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Background: Human papillomavirus (HPV) is well known as the major etiological agent for ano-genital cancer. In
contrast to cervical cancer, anal cancer is uncommon, but is increasing steadily in the community over the last few
decades. However, it has undergone an exponential rise in the men who have sex with men (MSM) and
HIV + groups. HIV +MSM in particular, have anal cancer incidences about three times that of the highest worldwide
reported cervical cancer incidences.
Discussion: There has therefore traditionally been a lack of data from studies focused on heterosexual men and
non-HIV +women. There is also less evidence reporting on the putative precursor lesion to anal cancer (AIN – anal
intraepithelial neoplasia), when compared to cervical cancer and CIN (cervical intraepithelial neoplasia). This review
summarises the available biological and epidemiological evidence for HPV in the anal site and the pathogenesis of
AIN and anal cancer amongst traditionally non-high risk groups.
Summary: There is strong evidence to conclude that high-grade AIN is a precursor to anal cancer, and some data
on the progression of AIN to invasive cancer.
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Approximately 15 of the 30–40 human papillomavirus
(HPV) types infecting the ano-genital mucosae (cervix,
vagina, vulva, anus and penis) are oncogenic viruses
causing ~ 5.2% of total human cancers [1]. Like cervical
cancer, squamous cell carcinoma of the anus (anal SCC)
is thought to be preceded by a spectrum of intra-
epithelial changes, anal intra-epithelial neoplasia (AIN),
of varying cytological and histological severity AIN 1 -
mild, AIN 2 - moderate, AIN 3 - severe, similar to cer-
vical intra-epithelial neoplasia (CIN), that correspond to
the CIN spectrum CIN 1, CIN 2/3 [2-4]. The success of
current HPV L1 prophylactic vaccines in preventing
high-grade dysplasia of the cervix (and consequently the
end-result of cancer) has raised the questions of whether
these vaccines will be successful in preventing other
HPV-related cancers, and whether subsequent licensing
of vaccine for non-cervical cancers is merited.* Correspondence: pg336@cam.ac.uk
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reproduction in any medium, provided the orIn this context, we will summarise the available evi-
dence that seeks to answer three questions which are
currently discussed for anal cancer and pre-cancers.
1) The lack of data on AIN and anal cancer from the
larger percentage of the community i.e. heterosexual
males and non-HIV-positive or non-high risk
women, which has meant that the majority of the
inferences are therefore extrapolated from MSM
data.
2) That AIN is a precursor lesion to invasive anal
cancer.




Anal SCC is an uncommon cancer but the incidence
worldwide is increasing in men and women [3]. Women
have a higher incidence rate in age groups greater than
50 years but men dominate the 20–49 year old age
group. In men and women, common risk factors are re-
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in women, additional risk factors are a history of high
grade vulvar intraepithelial neoplasia (VIN 3), cervical
intraepithelial cancer (CIN 3), vulvar cancer or cervical
cancer [4]. Immunosuppressed individuals, such as solid
organ transplant recipients and HIV-infected patients,
are also more susceptible to HPV-related cancers [5,6].
Most anal SCCs are a consequence of sexually or other-
wise acquired infection in the anal mucosa with onco-
genic HPV subtypes, predominantly HPV 16 [7].
In Scotland in the period 1975 to 2002 the incidence
of anal SCC doubled to 0.37 per 100,000 in men and
0.55 in women [8]. Data from the National Survey of
Sexual Attitudes and Lifestyles (NATSAL) in 2000
(quoted in [8]) indicates that in Scotland reported preva-
lence of anal intercourse in women (11.16%) was sub-
stantially higher than men (0.7%), indicating that this
behaviour may partially account for the observed differ-
ence in prevalence of anal cancer between the genders.
Furthermore, the anatomic proximity of the vaginal
introitus to the anus also facilitates non-sexual and
auto-inoculation in women via vaginal secretions, digital
or fomite transference [9,10]. The proportion of Scottish
women reporting the practice of anal intercourse is sig-
nificantly lower to similar studies in the U.S., where a
prevalence of 22 – 29% has been documented [11,12].
These discrepancies may represent true population be-
havioural differences or, perhaps more likely, under-
reporting. Even anonymised studies may show significant
bias when reporting behavioural aspects, especially when
studies are smaller. The overall risk for anal SCC is
linked to sexual behaviour between or within genders,
not sexual preference; increases in incidence were shown
before the advent of the HIV epidemic [3]. The majority
of studies of prevalence of anal HPV infection and AIN
have been in the MSM cohort, especially HIV-positive
MSM, as this is the highest risk group [13], but there are
also some data from high-risk HIV-positive and HIV-
negative women [14]. However, the paucity of data from
the heterosexual male and non-HIV-positive or non-
high risk female populations (largest sections of the gen-
eral population who make up a substantial number of
anal cancer patients) has been a problem in the clinical
management of these patients, particularly in determin-
ing the rationale and feasibility of instituting a screening
program. Nevertheless, it is likely that among men,
MSM account for a disproportionate amount of anal
intercourse and anal cancer.
Recent emerging data suggests that anal HPV (includ-
ing intra-anal and peri-anal HPV) infection is common.
Nyitray et al. 2008 [15] reported that the prevalence of
HPV DNA, detected in 222 heterosexual men, was
16.6% for the anal canal and 21.3% for the perianal area.
Of the patients with anal HPV infection, fully 33.3% hadan oncogenic high-risk HR-HPV type (as defined by
work from cervical cancer and its precursors). A recent
follow-up study by the same group, on men from Brazil,
Mexico and the USA has extended these findings [16].
In comparing only HIV-negative men (1305 heterosexual
versus 176 homosexual), they found anal canal HPV preva-
lence of 12.2% and 47.2% in these groups respectively. Two
previous studies examining heterosexual men i.e. Van
Doornum et al. 1994 [17], and Nicolau et al. 2005 [18], had
reported anal HPV DNA prevalences of 35% from 85 men
and 8% of men, respectively. The large discrepancies seen
are most likely due to differences in technique, sample
collection, different cohorts and, in particular, the use of
currently available highly sensitive PCR and line blot assays
with amplification steps.
Anal HPV infection data in HIV-negative women is
slightly better documented. The best available data
comes from the Hawaii HPV Cohort study; Hernandez
et al. 2005 [19] reported a baseline prevalence of 27%
anal HPV infection in this cohort. The same group has
now reported that during an average follow-up period of
1.3 years, 70% of the women developed incident anal
HPV infection [20]. Moscicki et al. 1999 [9] reported
that 66.7% of women with abnormal anal cytology had
detectable HPV compared to 12.7% of women with nor-
mal anal cytology. Finally, Palefsky’s group [14] reported
a prevalence of 42% in a cohort of HIV-negative women
with high-risk behaviour. The evidence is therefore
slowly accumulating that infection of the anal region
with HPV in both heterosexual men and non-HIV
infected women is relatively common.
Natural history studies and data on the role of persist-
ent anal infection with HPV in both sexes are consider-
ably less compared to that in women for cervical cancer.
The largest ongoing longitudinal study in women is that
by the investigators of the Hawaii HPV cohort where
they showed that in 431 women (followed at 4-monthly
intervals), 50% had an incident anal infection during a
mean duration of 1.2 years [21]. The median duration
for infection with a high-risk subtype was 150 days. This
group has further demonstrated that HPV anal infection
was likely to be sequentially acquired after initial cervical
infection, and that anal infection is cleared in 87% of
women within 1 year [22]. This is shorter than the generally
reported rate for the cervix (~90% cleared by 2 years) [23].
Interestingly, one study showed that 6 month persistence of
HPV 16 was absent in heterosexual men, whereas it oc-
curred in 5.1% of MSM patients [24].
These data may partially explain the finding that anal
cancer incidence is much lower than that for cervical
cancer if we accept the hypothesis that persistent infec-
tion with HPV is also required for anal cancer develop-
ment. High grade AIN (HGAIN) can be identified using
high-resolution anoscopy (HRA) or colposcopy of the
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However, in comparison to the number of cervical col-
poscopists, there are currently far fewer trained experts
in HRA and this partly explains why there is even less
data published on the prevalence of HGAIN in the gen-
eral population. Since there are no recommendations for
screening, many patients are either diagnosed serendipit-
ously during surgery for benign anal conditions or occa-
sionally during colonoscopy or if they present with anal
symptoms [25,26].
High grade intra-epithelial neoplasia at all ano-genital
sites (anus, cervix, vagina, vulva, penis) is likely to be a
precursor to invasive cancer at that site but the potential
for progression is best documented in the cervix as a
consequence of a large unethical study in which, during
the period 1955–1976, definitive treatment of CIN 3 was
withheld from a substantial cohort of New Zealand
women. The cumulative incidence of cancer of the cer-
vix or vaginal vault in this cohort was 31.3% at 30 years
as compared with 0.7% receiving adequate treatment
[27]. Clearly such a study cannot be duplicated at other
sites but progression of AIN to anal SCC has been
assessed in small studies with surveillance and treat-
ment, but with a relatively short follow up of 5–10 years.
Two studies conducted on HIV-negative cohorts stand
out. Scholefield’s group [28] has published on a cohort
of 35 HIV-negative patients (26 women and 9 men) with
AIN 3 and followed up for a median duration of
63 months (range 14 – 120 months). The median age
was 43 (range 31 – 62 years). Three of these 35 patients
(8.5%) developed invasive carcinoma at the sites of pre-
vious AIN 3 disease and all three were systemically im-
munosuppressed from long term oral therapy. The
authors suggest that immunosuppressed patients (6 in
this study – all from long term oral therapy, such as cor-
ticosteroids, for various conditions) and those with
multifocal AIN (7 in this study) are at higher risk of ma-
lignant transformation. This rate of malignant conver-
sion is not too dissimilar to that seen in VIN 3
conversion to vulvar cancer (~9% over 5 years) [29].
Another important study has reported on a cohort of
72 patients with AIN, followed for a median of
60 months (range 18–112 months) and with a median
age of 49 years (range 18 – 81 years) [30]. 8 patients
progressed to invasive SCC, 2 from AIN 2 (10 patients)
and 6 from AIN 3 (45 patients). Not one of 17 patients
with AIN 1 progressed to cancer during the follow-up
period. Twenty-five patients downgraded their lesions.
The authors suggest that since 13% of their AIN 3
patients converted to cancer during the follow-up
period, it is necessary to keep all AIN 3 under close sur-
veillance. However, the data from these 2 small studies
show that even with surveillance and treatment, on aver-
age 9-13% AIN 3 may progress to invasive disease over5–10 years, comparable to that observed for progression
of CIN 3 over similar time periods.
However, a recent meta-analysis has indicated that
progression rates from HGAIN to anal cancer are ap-
proximately one in 600 per year in HIV-positive MSM
and one in 4000 per year in HIV-negative MSM patients
[31], substantially lower than the one in 80 per year
observed in comparable cervical disease [27]. One pos-
sible explanation for this discrepancy is that these esti-
mates were based on multiple cross-sectional studies
and pooled prevalence rates of HGAIN and anal cancer
incidence rates, rather than prospective follow-up stud-
ies. However, it cannot be excluded that HGAIN might
regress more often than CIN 3, perhaps being partially
attributable to the fact that HGAIN encompasses both
AIN 2 and AIN 3, with AIN 2 probably containing a
mixture of HG and LG HPV types.
Summary
There are strong supportive data for the contention that
HGAIN is a precursor lesion to invasive anal carcinoma.
However, there are limited data on the prevalence of
HGAIN in the general population. There are also some
data giving estimates of the natural progression of AIN
into invasive cancer over different follow-up periods. Fi-
nally, there are current and very recent studies on anal
HPV infection in traditionally non-high risk groups con-
tinuing to emerge, which help to avoid mere extrapola-
tion of data from high-risk groups into the general
community. There is now a need for multi-centre pro-
spective studies on progression of AIN 3 to cancer and
on the effectiveness of treatment to reduce the incidence
of anal cancer.
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